Logo
Arrow
Xceed LoginConnect Now
Logo
Arrow
Arrow

Finished Dosage Forms - Product List:

Dr. Reddy’s Laboratories is a leading API supplier, with a presence in over 80 countries and a portfolio of 200+ ANDA filings and approved dossiers. Our offering goes beyond APIs and our global customers have access to high-quality dossiers and finished dosage forms.

Search
Therapy Areaarrow
Dosage Formarrow
Dossier Statusarrow
Therapy AreaProduct NameOralInjStrengthDossier StatusConnect
抗糖尿病Sitagliptin HCL + MetforminTick50 + 500, 50 + 850正在开发中Envelope
抗糖尿病Sitagliptin HCLTick25, 50, 100 mgFiledEnvelope
抗糖尿病Sitagliptin PhosphateTick25, 50 and 100 mgFiledEnvelope
抗糖尿病Sitagliptin Phosphate + MetforminTick50 + 500, 50 + 1000 mgFiledEnvelope
心血管的EltrombopagTick12.5, 25, 50 and 75 mgFiledEnvelope
心血管的Bempedoic acid EzetimibeTick180 mg/10 mg正在开发中Envelope
心血管的Bempedoic acidTick120 mg and 240 mg正在开发中Envelope
心血管的EdoxabanTick15 mg, 30 mg and 60 mg正在开发中Envelope
心血管的Tafamidis MeglumineTick20 mg正在开发中Envelope
中枢神经系统VigabatrinTickUSP 500 mgFiledEnvelope
中枢神经系统Edaravone60 mg/100 mlFiledEnvelope
中枢神经系统Topiramate ERTick25, 50, 100 and 200 mgFiledEnvelope
中枢神经系统CarboprostTickUSP Inj 250 mcg/ml PFSFiledEnvelope
中枢神经系统ColchicineTick0.6 mgFiledEnvelope
中枢神经系统Dimethyl FumarateTick120 mg and 240 mg正在开发中Envelope
肿瘤Busulfan6 mg/ml (10 ml)FiledEnvelope
肿瘤PazopanibTick200 and 400 mg正在开发中Envelope
肿瘤Bendamustine RTD45 mg/ml (4 ml) and 25 mg/ml (4 ml)FiledEnvelope
肿瘤Bortezomib3.5 mgFiledEnvelope
肿瘤FingolimodTick0.5 mgFiledEnvelope
Page 1 of 2

Product Capabilities

1R&D and Manufacturing Capabilities
Toggle
Research and DevelopmentManufacturing FacilitiesNich Product OpportunitiesVertical Integration
4 State-of-the-art R&D centres in India, U.K., U.S., and Netherlands 1200+ research scientists working on various projects11 formulations manufacturing facilitiesPeptides, Prostaglandins, HPAPIs, Innovative drug delivery, Novel dosage forms, Complex InjectablesMore than 60% of our formulations are backward integrated with our In- house API

Our 11 formulations manufacturing facilities that are operated in accordance with cGMP (ICH Q7a) and regularly inspected/audited by international regulatory authorities and customers (USFDA, MHRA, EMA, PMDA, TGA, SAHPRA, ANVISA, Russian MoH, CFDA, COFEPRIS and Health Canada).

2Product Capabilities
Toggle

Dr. Reddy's has an expertise of developing and manufacturing various dosage forms:

Oral SolidsInjectablesNovel Dosage Forms
Tablets, Chewable tablets, OrodispersibleLyophilized product and Liquid solutionEmulsions, Suspensions, Microspheres Liposomes tablets, Capsules, soft gel capsules Pellets a and Nanoparticles
3Service Capabilities
Toggle

Highly experienced and integrated technical team to support from filing-to-launch. Highly experienced technical and global regulatory teams with experience of 350+ Filings and 150+ approvals across B2B markets.

Regulatory servicesTech Transfer supportBio Study design support
Team of regulatory expertsComplete knowledge transferClinical pharmacokinetic team available
Support filing activitiesSupport local manufacturingDesign bio study protocol

Across multiple countries of interest

与我们的产品专家进行一对一的虚拟会谈

我们的专家将回答您的问题，提供建议、全球仿制药信息和紧迫的时间安排，帮助您更好地了解我们的产品

请求回电button arrow
meet with img
alt
alt

Global Presence

alt
  • altEurope
  • altMexico
  • altArgentina
  • altTurkey
  • altMena
  • altNorth Asia

Re-imagine API sourcing with Dr. Reddy's

免责声明

本網站上的任何信息，包括對任何產品或服務的任何提及，均不構成銷售要約或被解釋為代表銷售要約。受有效專利保護的產品不得提供或供應用於商業用途。但是，在某些情況下，雷迪博士可自行決定並根據當地法律要求，在存在此類監管豁免的任何地方，提供此類產品的研究數量，以根據《印度專利法》第 107A 條（Bolar 豁免）進行監管提交。購買者應對其各自市場的產品或服務（包括專利情況）進行獨立評估，並對所有與專利相關的責任負責。 Dr. Reddy's 不承擔任何明示或暗示的保證，包括但不限於適銷性、適用於特定用途和非侵權的保證。

Disclaimer: Products under patent(s) are offered only for R&D purposes U/S 107A of the Patent Act (Bolar Exemption) and not for commercial sale.